Biomark Diagnostic (BMKDF) 0.1030 $BMKDF
BIOMARK's Clinical Technology Center at Innovation Boulevard in Surrey BC
Filing Services Canada - Mon Apr 27, 7:02AM CDT
BIOMARKs Clinical Technology Center at Innovation Boulevard in Surrey BC Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (BioMark) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that it will be setting up an office at the Health Technology Innovation Hub located at 13737 96th Avenue, Surrey, BC starting May 1st 2015. President and CEO of BioMark, Rashid Ahmed says: This new office will be the Canadian clinical technology gateway center for BioMark as we develop and prime technologies for commercialization. The facilities, environment and location are an ideal convergence for technology development and testing. Accesses to physicians, researchers, instruments and active support from the Health Tech Innovation Foundation allow BioMark to practically accelerate our test, design and introduce medical technologies and solutions in an ideal setting. The facilities and site provides BioMark the perfect ecosystem to accelerate our technology development at point of care while leveraging the excellent resources available within this dynamic hub. About Innovation Boulevard Innovation Boulevard is an area consisting of 1 square mile in Surrey City Centre encompassing Surrey Memorial Hospital - Simon Fraser University - 3 other Academic institutions - 9 Technology Test beds and over 188 medical related businesses. Innovation Boulevard (http://www.surrey.ca/files/Innovation_Boulevard_Brochure_Jan_2015.pdf.pdf)is an agilepartnership of health, business, higher education and government creating new health technologies to improve peoples' lives. Its focus is on 3 technology areas: medical devices, independent living and digital health. Innovation Boulevards shared vision is to achieve remarkable results in4 areas: Improve health outcomes. Implement intelligent solutions for the health care system. Attract talented clinicians and researchers. Grow companies in health care technology and services sectors. About BioMark Diagnostics Inc. BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conductingPhase 3 multi site clinical trial for lung, breast, gastro intestinal and prostate cancers.Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com (http://www.sedar.com) and on the CSE website www.thecse.ca (http://www.thecse.ca). For further information on BioMark, please Contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-282-6567 Email: info@biomarkdiagnostics.com (mailto:info@biomarkdiagnostics.com) Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements. The CSE has not reviewed, approved or disapproved the content of this press release. To view this press release as a PDF file, click onto the following link: http://www.fscwire.com/sites/default/files/ne...272015.pdf Source: BioMark Diagnostics Inc (CSE:BUX) http://www.biomarkdiagnostics.com/ Maximum News Dissemination by FSCwire. http://www.fscwire.com Copyright(C)2015 Filing Services Canada Inc.
BIOMARK’s Clinical Technology Center at Innovation Boulevard in Surrey BC
Filing Services Canada XHTML - Mon Apr 27, 7:02AM CDT
BioMark Presents at 11th Annual Conference of the Metabolomics Society
Filing Services Canada XHTML - Tue Apr 14, 7:01AM CDT
BioMark Receives NSERC Engage Grant for Raman Enhancement with Dr. Safieddin Safavi-Naeini
Filing Services Canada XHTML - Tue Apr 07, 7:00AM CDT
BioMark Receives BIAP funding from NRC-IRAP
Filing Services Canada - Tue Mar 31, 7:04AM CDT
BioMark Receives BIAP funding from NRC-IRAP Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (BioMark) (CSE: BUX, FSE: 20B, OTCQB : BMKDF) is pleased to announce that it has been awarded by NRC IRAP the Business Innovation Access Program (BIAP) funding for development and optimization of its novel recombinant antibodies. Rashid Ahmed, President and CEO, comments This project will help optimize the potential production recombinant antibodies with work to be conducted by Dr. Bach at UBC. These antibodies will be critical in the commercial development of our cancer diagnostic kits. We are excited to be able to develop the antibodies with rich features that can help secure source and quality necessary for medical application kit development. BioMark would like to thank both NRC and UBC for their help in this endeavor that can yield both medical and economic benefit to Canada at large. About BioMark Diagnostics Inc. BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conductingPhase 3 multi site clinical trial for lung, breast, gastro intestinal and prostate cancers.Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com (http://www.sedar.com) and on the CSE website www.thecse.ca (http://www.thecse.ca). For further information on BioMark, please Contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-282-6567 Email: info@biomarkdiagnostics.com (mailto:info@biomarkdiagnostics.com) Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. The CSE has not reviewed, approved or disapproved the content of this press release. To view this press release as a PDF file, click onto the following link: http://www.fscwire.com/sites/default/files/ne...312015.pdf Source: BioMark Diagnostics Inc (CSE:BUX) http://www.biomarkdiagnostics.com/ Maximum News Dissemination by FSCwire. http://www.fscwire.com Copyright(C)2015 Filing Services Canada Inc.
BioMark Announces Partnership with the Metabolomics Innovation Centre
Filing Services Canada XHTML - Fri Mar 27, 7:01AM CDT
BioMark Added to CSE Composite Index
Filing Services Canada XHTML - Wed Mar 25, 7:02AM CDT
2015-0319 - Index - CSE Composite Index Quarterly Rebalancing
Marketwire Canada - Thu Mar 19, 3:06PM CDT
The quarterly rebalancing of the CSE Composite Index will result in the following changes, effective after the close on Friday, March 20, 2015.
SEE: 48.95 (-0.42), GFI: 3.84 (-0.02), BIS: 31.35 (-0.07), ACH: 16.33 (-0.21), BOI: 16.16 (-0.03)
BioMark Announces Grant Funded Partnership With TMIC
Filing Services Canada - Mon Mar 02, 7:04AM CST
BioMark Announces Grant Funded Partnership With TMIC Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (BioMark) (CSE: BUX, FSE: 20B, OTCQB : BMKDF) BioMark Diagnostics Inc. is proud to announce that it has obtained NSERC Engage Grant partnership funding in collaboration with Dr. David Wishart, Director of The Metabolomics Innovation Centre (TMIC) at the University of Alberta. President and CEO Rashid Ahmed says, We are delighted to enhance our collaboration with Dr. Wishart and TMIC at the University of Alberta. The collaboration to research, validate and establish additional biomarkers with a premier metabolic institution is testimony on the importance of metabolic tests for clinical and diagnostic applications. Dr. Wisharts expertise and TMICs infrastructure offers BioMark an ideal partnership. BioMark acknowledges and is thankful for the continued support and commitment from Natural Sciences and Engineering Research Council of Canada. About TMIC: The Metabolomics Innovation Centre (TMIC) is a Genome Canada funded Science & Technology Innovation Centre for metabolomics research, technology development and services. TMIC builds on metabolomics expertise at the University of Alberta and the University of Victoria, which includes nearly $20 million in state-of-the-art metabolomics equipment and ongoing investment for omics research and technologies by Genome Canada, Genome British Columbia and Genome Alberta. TMICs technologies are based on NMR, mass spectrometry, gas chromatography and novel bioinformatics tools to support clinical trial research, biomedical studies, agricultural studies, nutrient profiling and environmental testing for applications swww.metabolomicscentre.ca (http://www.metabolomicscentre.ca). About BioMark Diagnostics Inc. BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com (http://www.sedar.com) and on the CSE website www.thecse.ca (http://www.thecse.ca). For further information on BioMark, please Contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-282-6567 Email: info@biomarkdiagnostics.com (mailto:info@biomarkdiagnostics.com) Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements. The CSE has not reviewed, approved or disapproved the content of this press release. To view this press release as a PDF file, click onto the following link: http://www.fscwire.com/sites/default/files/ne...r22015.pdf Source: BioMark Diagnostics Inc (CSE:BUX) http://www.biomarkdiagnostics.com/ Maximum News Dissemination by FSCwire. http://www.fscwire.com Copyright(C)2015 Filing Services Canada Inc.
BioMark Announces a Final Closing Private Placement
Filing Services Canada XHTML - Wed Feb 18, 8:01AM CST
BioMark Announces OTCQB Listing
Filing Services Canada XHTML - Tue Feb 17, 10:43AM CST
BioMark Receives US Trading Symbol BMKDF from FINRA and Commences Trading in the USA
Filing Services Canada XHTML - Wed Jan 14, 1:40PM CST
BioMark to be on CBC Early Edition
Filing Services Canada XHTML - Wed Jan 14, 7:02AM CST
BIOMARK's Clinical Technology Center at Innovation Boulevard in Surrey BC
Filing Services Canada - Mon Apr 27, 7:02AM CDT
BIOMARKs Clinical Technology Center at Innovation Boulevard in Surrey BC Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (BioMark) (CSE: BUX, FSE: 20B, OTCQB: BMKDF) is pleased to announce that it will be setting up an office at the Health Technology Innovation Hub located at 13737 96th Avenue, Surrey, BC starting May 1st 2015. President and CEO of BioMark, Rashid Ahmed says: This new office will be the Canadian clinical technology gateway center for BioMark as we develop and prime technologies for commercialization. The facilities, environment and location are an ideal convergence for technology development and testing. Accesses to physicians, researchers, instruments and active support from the Health Tech Innovation Foundation allow BioMark to practically accelerate our test, design and introduce medical technologies and solutions in an ideal setting. The facilities and site provides BioMark the perfect ecosystem to accelerate our technology development at point of care while leveraging the excellent resources available within this dynamic hub. About Innovation Boulevard Innovation Boulevard is an area consisting of 1 square mile in Surrey City Centre encompassing Surrey Memorial Hospital - Simon Fraser University - 3 other Academic institutions - 9 Technology Test beds and over 188 medical related businesses. Innovation Boulevard (http://www.surrey.ca/files/Innovation_Boulevard_Brochure_Jan_2015.pdf.pdf)is an agilepartnership of health, business, higher education and government creating new health technologies to improve peoples' lives. Its focus is on 3 technology areas: medical devices, independent living and digital health. Innovation Boulevards shared vision is to achieve remarkable results in4 areas: Improve health outcomes. Implement intelligent solutions for the health care system. Attract talented clinicians and researchers. Grow companies in health care technology and services sectors. About BioMark Diagnostics Inc. BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conductingPhase 3 multi site clinical trial for lung, breast, gastro intestinal and prostate cancers.Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com (http://www.sedar.com) and on the CSE website www.thecse.ca (http://www.thecse.ca). For further information on BioMark, please Contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-282-6567 Email: info@biomarkdiagnostics.com (mailto:info@biomarkdiagnostics.com) Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements. The CSE has not reviewed, approved or disapproved the content of this press release. To view this press release as a PDF file, click onto the following link: http://www.fscwire.com/sites/default/files/ne...272015.pdf Source: BioMark Diagnostics Inc (CSE:BUX) http://www.biomarkdiagnostics.com/ Maximum News Dissemination by FSCwire. http://www.fscwire.com Copyright(C)2015 Filing Services Canada Inc.
BIOMARK’s Clinical Technology Center at Innovation Boulevard in Surrey BC
Filing Services Canada XHTML - Mon Apr 27, 7:02AM CDT
BioMark Presents at 11th Annual Conference of the Metabolomics Society
Filing Services Canada XHTML - Tue Apr 14, 7:01AM CDT
BioMark Receives NSERC Engage Grant for Raman Enhancement with Dr. Safieddin Safavi-Naeini
Filing Services Canada XHTML - Tue Apr 07, 7:00AM CDT
BioMark Receives BIAP funding from NRC-IRAP
Filing Services Canada - Tue Mar 31, 7:04AM CDT
BioMark Receives BIAP funding from NRC-IRAP Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (BioMark) (CSE: BUX, FSE: 20B, OTCQB : BMKDF) is pleased to announce that it has been awarded by NRC IRAP the Business Innovation Access Program (BIAP) funding for development and optimization of its novel recombinant antibodies. Rashid Ahmed, President and CEO, comments This project will help optimize the potential production recombinant antibodies with work to be conducted by Dr. Bach at UBC. These antibodies will be critical in the commercial development of our cancer diagnostic kits. We are excited to be able to develop the antibodies with rich features that can help secure source and quality necessary for medical application kit development. BioMark would like to thank both NRC and UBC for their help in this endeavor that can yield both medical and economic benefit to Canada at large. About BioMark Diagnostics Inc. BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer, early and cost effectively. BioMark is currently conductingPhase 3 multi site clinical trial for lung, breast, gastro intestinal and prostate cancers.Additionally trials related to assess response to lung cancer treatment and surgical interventions are being established. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com (http://www.sedar.com) and on the CSE website www.thecse.ca (http://www.thecse.ca). For further information on BioMark, please Contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-282-6567 Email: info@biomarkdiagnostics.com (mailto:info@biomarkdiagnostics.com) Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. The CSE has not reviewed, approved or disapproved the content of this press release. To view this press release as a PDF file, click onto the following link: http://www.fscwire.com/sites/default/files/ne...312015.pdf Source: BioMark Diagnostics Inc (CSE:BUX) http://www.biomarkdiagnostics.com/ Maximum News Dissemination by FSCwire. http://www.fscwire.com Copyright(C)2015 Filing Services Canada Inc.
BioMark Announces Partnership with the Metabolomics Innovation Centre
Filing Services Canada XHTML - Fri Mar 27, 7:01AM CDT
BioMark Added to CSE Composite Index
Filing Services Canada XHTML - Wed Mar 25, 7:02AM CDT
2015-0319 - Index - CSE Composite Index Quarterly Rebalancing
Marketwire Canada - Thu Mar 19, 3:06PM CDT
The quarterly rebalancing of the CSE Composite Index will result in the following changes, effective after the close on Friday, March 20, 2015.
SEE: 48.95 (-0.42), GFI: 3.84 (-0.02), BIS: 31.35 (-0.07), ACH: 16.33 (-0.21), BOI: 16.16 (-0.03)
BioMark Announces Grant Funded Partnership With TMIC
Filing Services Canada - Mon Mar 02, 7:04AM CST
BioMark Announces Grant Funded Partnership With TMIC Vancouver, British Columbia (FSCwire) - BioMark Diagnostics Inc. (BioMark) (CSE: BUX, FSE: 20B, OTCQB : BMKDF) BioMark Diagnostics Inc. is proud to announce that it has obtained NSERC Engage Grant partnership funding in collaboration with Dr. David Wishart, Director of The Metabolomics Innovation Centre (TMIC) at the University of Alberta. President and CEO Rashid Ahmed says, We are delighted to enhance our collaboration with Dr. Wishart and TMIC at the University of Alberta. The collaboration to research, validate and establish additional biomarkers with a premier metabolic institution is testimony on the importance of metabolic tests for clinical and diagnostic applications. Dr. Wisharts expertise and TMICs infrastructure offers BioMark an ideal partnership. BioMark acknowledges and is thankful for the continued support and commitment from Natural Sciences and Engineering Research Council of Canada. About TMIC: The Metabolomics Innovation Centre (TMIC) is a Genome Canada funded Science & Technology Innovation Centre for metabolomics research, technology development and services. TMIC builds on metabolomics expertise at the University of Alberta and the University of Victoria, which includes nearly $20 million in state-of-the-art metabolomics equipment and ongoing investment for omics research and technologies by Genome Canada, Genome British Columbia and Genome Alberta. TMICs technologies are based on NMR, mass spectrometry, gas chromatography and novel bioinformatics tools to support clinical trial research, biomedical studies, agricultural studies, nutrient profiling and environmental testing for applications swww.metabolomicscentre.ca (http://www.metabolomicscentre.ca). About BioMark Diagnostics Inc. BioMark is developing proprietary, non-invasive, and accurate cancer diagnostic solutions which can help detect, monitor and assess treatment for cancer early and cost effectively. The technology can also be used for measuring response to treatment and potentially for serial monitoring for cancer survivors. Further information about BioMark is available under its profile on the SEDAR website www.sedar.com (http://www.sedar.com) and on the CSE website www.thecse.ca (http://www.thecse.ca). For further information on BioMark, please Contact: Rashid Ahmed Bux President & CEO BioMark Diagnostics Inc. Tel. 604-282-6567 Email: info@biomarkdiagnostics.com (mailto:info@biomarkdiagnostics.com) Forward-Looking Information: This press release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of BioMark. Forward-looking information is based on certain key expectations and assumptions made by the management of BioMark. Although BioMark believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because BioMark can give no assurance that they will prove to be correct. Forward-looking statements contained in this press release are made as of the date of this press release. BioMark disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws. This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been and will not be registered under the United States Securities Act of 1933, as amended, or any applicable securities laws or any state of the United States and may not be offered or sold in the United States or to the account or benefit of a person in the United States absent an exemption from the registration requirements. The CSE has not reviewed, approved or disapproved the content of this press release. To view this press release as a PDF file, click onto the following link: http://www.fscwire.com/sites/default/files/ne...r22015.pdf Source: BioMark Diagnostics Inc (CSE:BUX) http://www.biomarkdiagnostics.com/ Maximum News Dissemination by FSCwire. http://www.fscwire.com Copyright(C)2015 Filing Services Canada Inc.
BioMark Announces a Final Closing Private Placement
Filing Services Canada XHTML - Wed Feb 18, 8:01AM CST
BioMark Announces OTCQB Listing
Filing Services Canada XHTML - Tue Feb 17, 10:43AM CST
BioMark Receives US Trading Symbol BMKDF from FINRA and Commences Trading in the USA
Filing Services Canada XHTML - Wed Jan 14, 1:40PM CST
BioMark to be on CBC Early Edition
Filing Services Canada XHTML - Wed Jan 14, 7:02AM CST
